Trials / Completed
CompletedNCT03835637
Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects
A Phase 1 Study of the Oral Glucocorticoid Receptor (GR) Antagonist ORIC-101 in Adult Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- ORIC Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This is a single centre, open-label, non-randomised study with up to 2 parts, assessing the safety, tolerability, PK and PD of single (Part A) and multiple (Part B; optional) doses of oral GR antagonist ORIC-101.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ORIC-101 | Capsule or oral suspension |
Timeline
- Start date
- 2018-03-23
- Primary completion
- 2018-07-04
- Completion
- 2018-07-04
- First posted
- 2019-02-08
- Last updated
- 2019-02-08
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03835637. Inclusion in this directory is not an endorsement.